Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors

Diagnostic Pathology

Ali Cetin²  Ersin Tuncer³  Meral Cetin²  Sema Arici¹  GoncaImir Yenicesu²  Hatice Ozer³ 

[1] Department of Pathology, BezmialemVakıf University, Faculty of Medicine, Sivas, Turkey;Department of Obstetrics and Gynecology, Cumhuriyet University, Faculty of Medicine, Sivas, Turkey;Department of Pathology, Cumhuriyet University, Faculty of Medicine, Sivas, 58140, Turkey

关键词: Metallothionein;    c-kit;    Telomerase;    bcl–2;    bax;    p21;    p53;    Immunohistochemistry;    Ovarian tumors;   

Others  :  807963
DOI  :  10.1186/1746-1596-7-124

 received in 2012-07-20, accepted in 2012-09-13,  发布年份 2012

【 摘 要 】

Background

In many tumors including ovarian cancer, cell proliferation and apoptosis are important in pathogenesis and there are many alterations in most of the genes related to the cell cycle. This study was designed to evaluate immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, and bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in typing of benign, borderline, and malignant serous and mucinous ovarian tumors.

Methods

Total of 68 ovarian tumors, 25 benign [13 (19.1%) serous and12 (17.6%) mucinous], 16 borderline [9 (13.2%) serous and 7(10.3%) mucinous], and 27 malignant ovarian tumors [24 (35.3%) serous and 3 (4.4%) mucinous tumors] were included in the study. Immunohistochemical expression of p53, p21, bax, bcl–2, telomerase, c-kit, and metallothionein were evaluated.

Results

When all 68 cases were evaluated as benign, borderline, and malignant ovarian tumors without considering histopathological subtypes, the p53, p21, bax and metallothionein showed significantly higher staining scores in the borderline and malignant ones (p < 0.05). After evaluation of all 68 cases, the serous tumors showed significantly higher staining scores of p53, p21, c-kit, and metallothionein compared to the mucinous ones (p < 0.05). For differentiation of benign and borderline and malignant tumors combined, p53 was not used because all benign tumors has no staining, and p21, bax, and metallothionein was determined the significant predictors for borderline and malignant tumors combined (p < 0.05). For differentiation of borderline and malignant tumors, only p53 was determined the significant predictor for malignant tumors (p < 0.05).

Conclusions

In conclusion, p53, p21, bax, c-kit, and metallothionein may be helpful for the typing of ovarian tumors as benign, borderline and malignant or serous and mucinous. p53, p21, bax, c-kit, and metallothionein may have different roles in the pathogenesis of ovarian tumor types. p53 and metallothionein may be helpful in the typing of borderline and malignant ovarian tumors. The immunohistochemical staining with bcl-2 and telomerase may not provide meaningful contribution for the typing of ovarian tumors.

Virtual slide

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2013030833768498 webcite

【 授权许可】

   
2012 Ozer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]McGuire WP: Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Onco 2009, 27:4633-4634.
• [2]Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study Cancer 1986, 57(9):1725-1730.
• [3]Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, ICBP Module 1 Working Group: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127-38.
• [4]Seidman JD, Russel P, Kurman RJ: Surface epithelial tumors of the ovary, (Chapter 18). In In Blaustein’s Pathology of the Female Genital Tract. 5th edition. Edited by Kurman RJ. New York: Springer; 2002:791-904.
• [5]Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, Hauptmann S, Rutgers J: WHO Histological Classification of Tumours of the ovary (Chapter 2). In In Pathology and Genetics of Tumours of the Breast and Female Genital organs. Edited by Tavassoli FA, Devilee P. Lyon: IARC Pres; 2003:113-161.
• [6]Skirnisdottir I, Sorbe B, Seidal T: P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int J Gynecol Cancer 2001, 11:147-158.
• [7]Fauvet R, Dufornet C, Poncelet C, Uzan C, Hugol D, Darai E: Expression of Pro-Apoptotic (p53, p21, bax, bak and fas) and Anti-Apoptotic (bcl-2 and bcl-x) Proteins in Serous Versus Mucinous Borderline Ovarian Tumours. J Surg Oncol 2005, 92:337-343.
• [8]Kim DJ, Lee MH, Park TI, Bae HI: Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. J Korean Med Sci 2006, 21:81-85.
• [9]Mccluggage WG, Strand K, Abduldair A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer 2002, 12:62-65.
• [10]Schuyer M, Van der Burg M, Henzen-Logmans SC, Fieret JH, Klijn JGM, Look MP, Foekens JA, Stoter G, Berns EM: Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 2001, 85(9):1359-1367.
• [11]Datar RH, Naritoku WY, Li P, Tsao-Wei D, Groshen S, Taylor CR, Imam SA: Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas. Gynecol Oncol 1999, 74:338-345.
• [12]Kyo S, Kanaya T, Takakura M, Tanaka M, Yamashita A, Inoue H, Inoue M: Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer 1999, 80:804-809.
• [13]Tonary AM, Macdonald EA, Faught W, Senterman MK, Vanderhyden BC: Lack of expression of C-Kit in ovarian cancers is associated with poor prognosis. Int J Cancer (Pred Oncol) 2000, 89:242-250.
• [14]Brustmann H: Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: A clinicopathologic study. Gynecol Oncol 2005, 98:396-402.
• [15]Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemuller J, Schiffer I, Oesch F, Knapstein PG, Kaina B, Tanner B: Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer (Pred Oncol) 2001, 95:121-127.
• [16]Wrigley E, Verspaget HW, Jayson GC, Mcgown AT: Metallothionein expression in epithelial ovarian cancer effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 2000, 126:717-721.
• [17]Hartmann L, Podratz K, Keeney G, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994, 12:64-69.
• [18]Havrilevsky L, Darcy K, Hamdan R, Priore RL, Leon J, Bell J, Berchuck A: Prognostic significance of p53 mutation and p53 overerpression in advanced epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2003, 21:3814-3825.
• [19]Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A: Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004, 14:1086-1096.
• [20]Mireskandari M, Shafaii AF, Kayser G, Kayser K: Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature. Diagn Pathol 2006, 1:7. BioMed Central Full Text
• [21]Parrott JA, Kim G, Skinner MK: Expression and action of Kit Ligand/ Stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod 2000, 62:1600-1609.
• [22]Surowiak P, Materna V, Adam MA, Pudelko M, Markwitz E, Spaczynski M, Dietel M, Zabel M, Lage H: Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 2007, 450:279-285.
• [23]Tan Y, Sinniah R, Bay BH, Singh G: Expression of metallothionein and nuclear size in discrimination of malignancy in mucinous ovarian tumors. Int J Gynecol Pathol 1999, 18(4):344-350.
• [24]Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG: Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998, 82:893-901.
• [25]Vang R, Shih IM, Kurman RJ: Ovarian low-grade and high-grade serous carcinoma pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009, 16:267-282.
• [26]Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih IM: Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis A Mutational Analysis With Immunohistochemical Correlation. Am J Surg Pathol 2005, 29(2):218-224.
• [27]Hogg R, Scurry J, Kim SN, Friedlander M, Hacker N: Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Gynecol Oncol 2007, 106:44-51.
• [28]Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN: Expression of C-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors. Reprod Sci 2008, 15(7):673-677.
• [29]Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barres V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson AM: Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer 2008, 8:346-353. BioMed Central Full Text
• [30]Luo Y, Yi Y, Yao Z: Growth arrest in ovarian cancer cells by hTERT inhibition short-hairpin rna targeting human telomerase reverse transcriptase induces immediate growth inhibition but not necessarily induces apoptosis in ovarian cancer cells. Cancer Invest 2009, 27:960-970.
• [31]Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M: Augmented expression of metallothionein and glutathione S-transferase pi as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005, 447:626-633.
• [32]Li M, Qi SY, Wang Y, Feng SX, Zhang BZ, Wang R: Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors. Arch Gynecol Obstet 2005, 272:48-52.
• [33]Abo-Elwafa HA, Attia FM, Sharaf AEA: The prognostic value of p53 mutation in pediatric marrow hypoplasia. Diagn Pathol 2011, 6:58. BioMed Central Full Text
• [34]Barisik NO, Bozkurt S, Gumus M, Kaygusuz I, Karadayi N, Bas E, Bayik M, Tecimer T: Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study. Diagn Pathol 2010, 5:19. BioMed Central Full Text
• [35]Sagarra RAM, Andrade LA, Martinez EZ, Pinto GA, Syrjanen KJ, Derchain SF: p53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer 2002, 12:720-727.
• [36]Lee H, Park G, Jung JH, Ahn WS, Lee JM, Kim BK, Kang CS: Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors. Int J Gynecol Cancer 2005, 15(3):453-461.
• [37]Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA: Bax protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998, 16:2583-2590.
• [38]Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC: Bcl-2 ve p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000, 156:409-417.
• [39]O’neill CJ, Deavers MT, Malpica A, Foster H, Mccluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005, 29(8):1034-1041.
• [40]Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. J Med Assoc Thai 2009, 92(3):308-314.
• [41]Sun PM, Wei LH, Luo MY, Liu G, Wang JL, Mustea A, Könsgen D, Lichtenegger W, Sehouli J: The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. EJOG 2007, 130:249-257.
• [42]Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N, Agnantis NJ: Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol 2006, 21(4):341-347.